羟氯喹治疗类风湿关节炎与抑郁、自杀及精神病风险:多国网络队列研究
该研究基于德国、英国和美国10个数据源的新用户队列,比较起始羟氯喹与起始柳氮磺吡啶的类风湿关节炎患者,随访短期(30天)和长期(治疗期间)。结果显示,与柳氮磺吡啶相比,羟氯喹使用者的抑郁、自杀/自杀意念及精神病住院风险均无一致升高,短期和长期均未见明显风险。
要点
- 羟氯喹治疗类风湿关节炎未增加短期抑郁、自杀/自杀意念或精神病风险。
- 长期治疗期间同样未观察到上述精神事件风险升高。
- 更高剂量或不同适应症的精神风险仍需进一步研究。
核心结论
- 与柳氮磺吡啶相比,用于治疗类风湿关节炎的羟氯喹不增加抑郁、自杀/自杀意念或精神病风险。
- 短期和长期随访均未观察到上述精神事件风险升高。
研究设计与样本
- 多国网络新用户队列研究,使用10个数据源、3个国家(德国、英国、美国)的理赔与电子病历数据。
- 纳入≥18岁起始羟氯喹的类风湿关节炎患者,以起始柳氮磺吡啶为活性对照,随访短期(30天)和长期(治疗期间)。
- 采用倾向评分分层和阴性对照结局校准控制混杂,Cox模型估计校准风险比,I2<40%时合并。
主要发现
- 短期羟氯喹对比柳氮磺吡啶的荟萃分析HR:抑郁0.96(95%CI 0.79, 1.16),自杀/自杀意念0.94(95%CI 0.49, 1.77),精神病1.03(95%CI 0.66, 1.60)。
- 长期羟氯喹对比柳氮磺吡啶的荟萃分析HR:抑郁0.94(95%CI 0.71, 1.26),自杀/自杀意念0.77(95%CI 0.56, 1.07),精神病0.99(95%CI 0.72, 1.35)。
临床怎么用
- 对于类风湿关节炎患者,使用羟氯喹时无需因担心抑郁、自杀或精神病风险而常规调整监测策略。
- 高剂量或非类风湿关节炎适应症的精神风险尚需进一步研究,临床决策应结合具体情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Concern has been raised in the rheumatology community regarding recent regulatory warnings that HCQ used in the coronavirus disease 2019 pandemic could cause acute psychiatric events. We aimed to study whether there is risk of incident depression, suicidal ideation or psychosis associated with HCQ as used for RA. METHODS: We performed a new-user cohort study using claims and electronic medical records from 10 sources and 3 countries (Germany, UK and USA). RA patients ≥18 years of age and initiating HCQ were compared with those initiating SSZ (active comparator) and followed up in the short (30 days) and long term (on treatment). Study outcomes included depression, suicide/suicidal ideation and hospitalization for psychosis. Propensity score stratification and calibration using negative control outcomes were used to address confounding. Cox models were fitted to estimate database-specific calibrated hazard ratios (HRs), with estimates pooled where I2 <40%. RESULTS: A total of 918 144 and 290 383 users of HCQ and SSZ, respectively, were included. No consistent risk of psychiatric events was observed with short-term HCQ (compared with SSZ) use, with meta-analytic HRs of 0.96 (95% CI 0.79, 1.16) for depression, 0.94 (95% CI 0.49, 1.77) for suicide/suicidal ideation and 1.03 (95% CI 0.66, 1.60) for psychosis. No consistent long-term risk was seen, with meta-analytic HRs of 0.94 (95% CI 0.71, 1.26) for depression, 0.77 (95% CI 0.56, 1.07) for suicide/suicidal ideation and 0.99 (95% CI 0.72, 1.35) for psychosis. CONCLUSION: HCQ as used to treat RA does not appear to increase the risk of depression, suicide/suicidal ideation or psychosis compared with SSZ. No effects were seen in the short or long term. Use at a higher dose or for different indications needs further investigation. TRIAL REGISTRATION: Registered with EU PAS (reference no. EUPAS34497; http://www.encepp.eu/encepp/viewResource.htm? id=34498). The full study protocol and analysis source code can be found at https://github.com/ohdsi-studies/Covid19EstimationHydroxychloroquine2.
引用
- Lane JCE, Weaver J, Kostka K, et al. Risk of depression, suicide and psychosis with hydroxychloroquine treatment for rheumatoid arthritis: a multinational network cohort study. Rheumatology (Oxford). 2021. PMID: 33367863. doi:10.1093/rheumatology/keaa771
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。